Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 in Neuromyelitis Optica Spectrum Disorders
NCT03330418Phase 3Terminated
- Sponsor
- RemeGen
- Start
- Jan 2018
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by RemeGen. Started Jan 2018; status: terminated.
02
Drugs
telitacicept
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT03330418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330418.